COVID-19 and Phytotherapy

被引:4
|
作者
Akbas, Melike Nur [1 ]
Akcakaya, Adem [2 ]
机构
[1] Bezmialem Vakif Univ, Phytopharm, Istanbul, Turkey
[2] Bezmialem Vakif Univ, Fac Med, Dept Gen Surg, Istanbul, Turkey
来源
BEZMIALEM SCIENCE | 2020年 / 8卷 / 04期
关键词
COVID-19; coronavirus; phytotherapy; comlementary therapy; RESPIRATORY-TRACT INFECTIONS; DOUBLE-BLIND; SAMBUCUS-NIGRA; ELDERBERRY; EXPRESSION; LICORICE; CURCUMIN; INJURY;
D O I
10.14235/bas.galenos.2020.4962
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2), emerging in Wuhan city, China, causing COVID-19 disease, has been described as a pandemic by WHO (World Health Organization), leading to outbreaks of pneumonia. The COVID-19 pandemic continues to affect millions of people worldwide. SARS-COV-2 enters the cell via ACE-2 (Angiotensin-converting enzyme 2) receptor. These receptors are predominantly found in lung, small intestine, and vascular endothelial cells. Since ACE 2 is found more frequently in these tissues, common clinical symptoms include fever, cough, sore throat, fatigue, dyspnea, and diarrhea. Currently, although symptomatic treatments are applied for COVID-19, there is no specific treatment yet. It takes a long time before targeted therapies can be found. For this reason, it is necessary to develop emergency treatment or methods that can quickly control the disease. Phytotherapeutic compositions offer a potentially valuable resource for this purpose. Many countries, especially China, aimed to reduce morbidity and mortality by using phytotherapy throughout COVID-19 patients. Phytotherapeutic products are known to be safe and tolerable with their background knowledge. In this regard, the use of phytotherapy as a complementary treatment in COVID-19 patients is very important. In this review, phytotherapeutic approaches related to symptoms that may occur in the clinical course of COVID-19 disease will be discussed.
引用
收藏
页码:428 / 437
页数:10
相关论文
共 50 条
  • [31] COVID-19 and stroke
    Herzig, R.
    Mikulik, R.
    Tomek, A.
    Neumann, J.
    Skoloudik, D.
    CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE, 2021, 84 (01) : 31 - 37
  • [32] Asthma and COVID-19
    Celebioglu, Ebru
    ASTIM ALLERJI IMMUNOLOJI, 2020, 18 (01): : 56 - 57
  • [33] COVID-19 reinfections
    Fabianova, K.
    Kyncl, J.
    Vlckova, I
    Jirincova, H.
    Kostalova, J.
    Liptakova, M.
    Orlikova, H.
    Sebestova, H.
    Limberkova, R.
    Mackova, B.
    Maly, M.
    EPIDEMIOLOGIE MIKROBIOLOGIE IMUNOLOGIE, 2021, 70 (01): : 62 - 67
  • [34] Metainflammation in COVID-19
    Bakhtiari, Mojtaba
    Asadipooya, Kamyar
    ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS, 2022, 22 (12) : 1154 - 1166
  • [35] COVID-19 and water
    Bellie Sivakumar
    Stochastic Environmental Research and Risk Assessment, 2021, 35 : 531 - 534
  • [36] COVID-19 and Indonesia
    Setiati, Siti
    Azwar, Muhammad K.
    ACTA MEDICA INDONESIANA, 2020, 52 (01) : 84 - 89
  • [37] Diabetes and COVID-19
    Bouhanick, Beatrice
    Cracowski, Jean-Luc
    Faillie, Jean-Luc
    THERAPIE, 2020, 75 (04): : 327 - 333
  • [38] COVID-19 and water
    Sivakumar, Bellie
    STOCHASTIC ENVIRONMENTAL RESEARCH AND RISK ASSESSMENT, 2021, 35 (03) : 531 - 534
  • [39] COVID-19 and the kidneys
    Rohn, H.
    Feldkamp, T.
    Witzke, O.
    GASTROENTEROLOGE, 2020, 15 (06): : 471 - 476
  • [40] Coagulopathy in COVID-19
    Iba, Toshiaki
    Levy, Jerrold H.
    Levi, Marcel
    Thachil, Jecko
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2020, 18 (09) : 2103 - 2109